Mental DisordersPMNPNCT06580860
Psychiatric Multi-omics and Neuroimaging Project
An observational study of Mental Disorders and Healthy Control, run by mingjun Zhong at 1 site in China.
Trial summary
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Read more about this study
- Who is it for?
- Ages 13 to 35 yearsHealthy volunteers can take part
- Conditions the study is for
- Mental Disorders, Healthy Control
- What is being tested?
- Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
- How many people
- 1,899 participants
- Where
- 1 siteChina
- Study dates
- Jan 2016to Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 35 years
- All sexes
- Healthy volunteers accepted
- Child, Adult
Study population: Patients from inpatient and outpatient the second Xiangya Hosptial of Central South University, Healthy controls from community, school and street recruitment
Who may be able to join
- Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
- Course of disease: <24 months
- Priority is given to patients who have never taken medicine or duration of drug use < 2 weeks
- No nuclear magnetic contraindications.
Who cannot join
- Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
- Have a major physical disease or infectious disease
- History of coma and serious neurological disease 4.MRI contraindications.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The Second Xiangya hospital of central south univerity
Changsha, Hunan, 410000
Yunzhi Pan, 15074818197, panyunzhi@csu.edu.cn
About this study
Official title: Psychiatric Multi-omics and Neuroimaging Project Database
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
Read the detailed description
The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.
- Conditions
- Mental Disorders, Healthy Control
- Being tested
- Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids
- Keywords
- schizophrenia, major depressive disorder, autism spectrum disorder, bipolar disorder, magnetic resonance imaging, multi-omics
- Medical subject headings
- Mental Disorders, Schizophrenia, Depressive Disorder, Major, Autism Spectrum Disorder, Bipolar Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aidsDrug
Patients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors.
| Study group | Role | What they receive |
|---|---|---|
| PMNP-Healthy Norms | Healthy Norms Receives: Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids | |
| PMNP-Subclinical high-risk | Subclinical high-risk Receives: Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids | |
| PMNP-Schizophrenia and Psychosis | Schizophrenia and Psychosis patient Receives: Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids | |
| PMNP-MDD | major depressive disorder patient Receives: Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids | |
| PMNP-ASD | autism spectrum disorder patient Receives: Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids | |
| PMNP-BD | bipolar disorder patient Receives: Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aids |
What is being measured
The primary outcome is the main question the study is designed to answer.
cortical morphology
Data were obtained using magnetic resonance scans
Measured: 40 minutes
target gene charaacteristics
10ml peripheral blood was extracted for gene analysis
Measured: 1 day
scale scores
The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.
Measured: 90 minutes.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2024
- Study startJan 2016
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Mental DisordersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,899 participants (estimated)
Sponsor and investigators
- Lead sponsor
- mingjun Zhong
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, mingjun Zhong, Second Xiangya Hospital of Central South University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06580860
- Sponsor's protocol ID
- NSFC82201664
- Acronym
- PMNP
- Status last verified
- Mar 2026
- First submitted
- 28 Aug 2024
- Last updated
- 13 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Psychiatric Multi-omics and Neuroimaging Project Database
- ClinicalTrials.gov ID
- NCT06580860
- Acronym / sponsor ID
- PMNP / NSFC82201664
- Conditions
- Mental Disorders, Healthy Control
- Keywords
- schizophrenia, major depressive disorder, autism spectrum disorder, bipolar disorder, magnetic resonance imaging, multi-omics
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 1,899 participants (estimated)
- Lead sponsor
- mingjun ZhongUniversity, hospital or other
- Study start
- Jan 2016 (actual)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 30 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study focuses on the structure and function of the brain and gene expression in peripheral blood of patients with schizophrenia, to explore the interaction and influence between the three. Patients with mental disorders who have been recruited will take their medication regularly for 1 year and participate in baseline and follow-up assessments.
Detailed description
The study seeks to identify possible biological markers of schizophrenia and the effects of gene-environment interactions on brain structural and functional networks. So we can help doctors and scientific researchers better understand the neuropathological basis of schizophrenia.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| PMNP-Healthy Norms | – | Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aidsHealthy Norms |
| PMNP-Subclinical high-risk | – | Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aidsSubclinical high-risk |
| PMNP-Schizophrenia and Psychosis | – | Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aidsSchizophrenia and Psychosis patient |
| PMNP-MDD | – | Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aidsmajor depressive disorder patient |
| PMNP-ASD | – | Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aidsautism spectrum disorder patient |
| PMNP-BD | – | Drug: Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aidsbipolar disorder patient |
Who may qualify
- Ages
- 13 to 35 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
- Study population
- Patients from inpatient and outpatient the second Xiangya Hosptial of Central South University, Healthy controls from community, school and street recruitment
Key inclusion criteria (4 listed)
- Age: 13-35 years old(Patients with healthy siblings can be extended to 14-35 years of age)
- Course of disease: <24 months
- Priority is given to patients who have never taken medicine or duration of drug use < 2 weeks
- No nuclear magnetic contraindications.
Key exclusion criteria (3 listed)
- Family history of psychotic disorders, history of psychoactive substances abuse, alcohol dependence, or nicotine dependence
- Have a major physical disease or infectious disease
- History of coma and serious neurological disease 4.MRI contraindications.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antipsychotic drugs, antidepressants, mood stabilizers, and sleep aidsPatients with mental disorders should take the appropriate medicine as prescribed by the doctor，and the health norms are not required to take medicine.This study will not interfere with the medication regimen of doctors. | Drug | PMNP-ASD, PMNP-BD, PMNP-Healthy Norms, PMNP-MDD, PMNP-Schizophrenia and Psychosis, PMNP-Subclinical high-risk |
Primary outcome
cortical morphology
Time frame: 40 minutes
Data were obtained using magnetic resonance scans
target gene charaacteristics
Time frame: 1 day
10ml peripheral blood was extracted for gene analysis
scale scores
Time frame: 90 minutes.
The score of each dimension and the total score were calculated according to the scale.The scale includes three dimensions: negative symptom, positive symptom and general psychopathology, and the score range of each dimension is different. The total score ranges from 30 to 210, with higher scores indicating worse results.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2026.
Related trials for Mental Disorders
Recruiting
Electrotherapy Stimulation Together With Life Coaching for the Support of Burnout Symptoms in Healthcare Workers
Psychiatric Disorder
Not yet recruiting
Inflammatory Pathways Modulated by Prenatal Mindfulness: A Route to Improve Maternal Child Emotional Well Being and Whole Person Health
Inflammation, Depression Disorder
Active, not recruiting
A Study to Evaluate the Effects of a Beef Liver Supplement on Energy, Mood, and Mental Clarity
Fatigue, Low Mood
Recruiting
Pilot Study on the Acceptability of Auricular Vagus Nerve Neurostimulation in Adolescents
Psychiatric Disorder
Active, not recruiting
Impact of Anesthesia Alarm Volume on Mental Workload in Surgical Trainees
Surgical Procedures, Noise
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Mental Disorders and Healthy Control, run by mingjun Zhong at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Yunzhi Pan (15074818197, panyunzhi@csu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
cortical morphology (time frame: 40 minutes). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2026; AzTrials last refreshed its copy on 26 Oct 2026.